Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Astellas Pharma Adds Medical Expertise | Contract Pharma
Breaking News, Promotions & Moves

Astellas Pharma Adds Medical Expertise

Weinberg and McGarry to head global clinical science and medical safety

Mark Weinberg, M.D. has been promoted to vice president of Global Clinical Science, and Robin J. McGarry, M.D. has been appointed vice president, global medical safety head at Astellas Pharma Global Development, Inc. (APGD).
 
Dr. Weinberg joined the company in 2011 as the global therapeutic area head in CNS and Pain. He has more than 14 years of experience in the pharmaceutical industry, working across multiple therapeutic areas. Prior to Astellas he was at Lundbeck, where he focused on CNS.   
 
Dr. McGarry has more than 25 years of experience in the pharmaceutical industry, including positions in clinical development and medical affairs, and served as vice president, Worldwide Safety at Pfizer. For the past 13 years, she has worked as an independent consultant, providing pharmacovigilance, clinical, and regulatory strategic consulting services. 

“Since its inception in 2008, APGD has been a driving force in Astellas’ mission of developing innovative medicines for patients in need, said Dr. Sef Kurstjens, chief medical officer of Astellas and president of APGD. “We are thrilled to be promoting Mark and bringing Robin onto the Astellas team to further that mission.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters